



Contact:

David Waldman or Justyna Gudaszevska
Crescendo Communications Europe Sp. z o.o.
Email: mmd@crescendo-ir.com
Tel: + 48 71 79 11 551

**Milestone Medical Announces the Start of Epidural Instrument Clinical Trials
at a Major Pain Management Center in the United States**

LIVINGSTON, NJ, March 5, 2015 -- Milestone Medical Inc. (WAR: MMD) today announced the start of its pivotal clinical trial for its epidural instrument at a major pain management center in the United States. Milestone Medical has also met FDAAA 801 requirements for submission of the clinical trial information to the Director of the National Institutes of Health (NIH) for inclusion in the registry and results database established via ClinicalTrials.gov for its CompuFlo Epidural Computer Controlled System for assessing the safety and effectiveness of the instrument for identifying the epidural space. Recruitment for the clinical trial is underway and the first patients are now taking part in the study.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "We appreciate the support and cooperation we have received from one of the most advanced and best equipped pain management centers in United States. This clinic has some of the leading board certified physicians, as well as a large number of existing patients suffering a variety of complications requiring epidurals. We believe our epidural instrument has the potential to help improve the treatment of chronic pains, while improving safety of the injection for the patient and reducing malpractice risk for the medical practitioner. Clinical trials will serve as an important step forward and validation of our pressure sensing injection technology in the U.S. Upon completion of the clinical trials, we will then conduct a statistical analysis of the studies, at which time we plan to return to the FDA for final marketing clearance for our epidural instrument."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and has recently received CE approval for both instruments in the European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.